SCHEMBL25202091

SCHEMBL25202091

COc1cc(/C=C/C(=O)c2ccc(O)cc2)ccc1OCc1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
LMNA P02545 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ALDH1A1 P00352 2/20 0.58
CXCL12 P48061 2/20 0.54
CXCR4 P61073 1/20 0.54
ABCG2 Q9UNQ0 4/20 0.51
ACHE P22303 1/20 0.49
BACE1 P56817 1/20 0.49
CTSL P07711 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
CA2 P00918 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
CA1 P00915 1/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.47
TNFRSF1A P19438 1/20 0.47
CA5A P35218 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25284512 0.92 MAPT (0.59) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25201243 0.91 LMNA (0.60) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25211823 0.88 MAPT (0.54) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25231541 0.84 POLB (0.58) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25223482 0.82 MEN1 (0.59) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25216250 0.80 MAPT (0.58) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25203931 0.79 POLB (0.56) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL25201954 0.79 ALDH1A1 (0.55) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL8899587 0.78 MAPT (0.51) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL13613545 0.76 ABCG2 (0.86) MAPTLMNAMEN1KMT2ACXCL12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885LMNA 1180/4885MEN1 3367/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885MEN1 2457/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885MEN1 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.